Adaptive Biotechnologies (ADPT) Asset Writedowns and Impairment (2024 - 2026)

Adaptive Biotechnologies has disclosed Asset Writedowns and Impairment across 3 years of filings, most recently posting $347000.0 for Q1 2026.

• Asset Writedowns and Impairment for Q1 2026 came in at $347000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $910000.0 (changed N/A YoY), and the FY2025 annual result was $563000.0, down 70.95% from the prior year.
• Asset Writedowns and Impairment came in at $347000.0 for Q1 2026 at Adaptive Biotechnologies, down from $563000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $563000.0 in Q4 2025 to a low of -$5.3 million in Q4 2024.
• The 3-year median for Asset Writedowns and Impairment is $347000.0 (2026), against an average of -$1.5 million.
• Peak annual rise in Asset Writedowns and Impairment reached 110.69% in 2025, while the deepest fall reached 110.69% in 2025.
• Adaptive Biotechnologies' Asset Writedowns and Impairment stood at -$5.3 million in 2024, then surged by 110.69% to $563000.0 in 2025, then tumbled by 38.37% to $347000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $347000.0 (Q1 2026), $563000.0 (Q4 2025), and -$5.3 million (Q4 2024), per Business Quant data.